Explore the evolving landscape of hormone therapies in prostate cancer treatment with insights from expert physicians as they delve into the latest options, indications, and their impact on patient care.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.